# 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

> **NCT01378104** · PHASE4 · COMPLETED · sponsor: **The Catholic University of Korea** · enrollment: 178 (actual)

## Conditions studied

- Sustained Virologic Response
- IL28B Polymorphism

## Interventions

- **DRUG:** peginterferon alfa 2a (pegasys)
- **DRUG:** peginterferon alfa-2a (pegasys)

## Key facts

- **NCT ID:** NCT01378104
- **Lead sponsor:** The Catholic University of Korea
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-09
- **Final completion:** 2012-09
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2013-03-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378104, "100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01378104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*